Rona Therapeutics Submits Clinical Trial Application in Australia for RN3161, a Novel siRNA Therapy Targeting INHBE to Enable Fat Loss While Preserving Lean Body Mass

September 15,Rona Therapeutics announced that the company's self-developed RN3161 has submitted a clinical trial application to the Australian Human Research Ethics Committee (HREC). RN3161 is a GalNAc-siRNA targeting INHBE, designed to provide a sustainable weight-loss therapy for overweight and obese populations.

INHBE has become a high-potential target for improving obesity treatment.Research has found,INHBEThe gene is mainly expressed in the liver and encodes the Activin E protein, which regulates lipid metabolism. Some individuals who carryINHBESpecific gene variants often exhibit healthier fat distribution and body composition, more ideal blood lipid levels, and significantly reduce the risk of type 2 diabetes and cardiovascular diseases.

RN3161Able to achieve precise silencingINHBEReduce fat while maintaining lean body mass, thereby distinguishing itself from existing weight-loss treatments. The optimized GalNAc delivery design combined with chemical modifications of this product reduces off-target risks. In preclinical studies, a single low-dose administration resulted in over 90% downregulation of INHBE mRNA expression, demonstrating strong efficacy and persistence.Preclinical studies show that RN3161 can achieve a gene silencing effect lasting over six months, with the potential to reduce dosing frequency to just 1–2 times per year.Significantly enhance patient compliance and long-term management potential.

Chief Medical Officer (CMO) of Rona Therapeutics, Dr. Alex M. DePaoliIndicates, RN3161Not only is it expected to help patients lose weight while maintaining muscle mass, but it may also amplify the metabolic benefits associated with fat reduction.At the same time, low-frequency dosing can improve compliance and help maintain weight, providing a new treatment paradigm for obesity management.

References:
[1] Rona Therapeutics Announces Acceptance of RN3161 Australian Clinical Trial Application. From https://www.prnasia.com/story/503525-1.shtml

Disclaimer: This article is for information exchange purposes only. The views expressed in the article do not represent the position of WuXi AppTec, nor does WuXi AppTec support or oppose the views mentioned in the article. This article is not a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.